•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
Coeur Mining, Inc. (NYSE:CDE) Given Consensus Rating of “Moderate Buy” by Brokerages
Coeur Mining Is No Longer Cheap, But Growth Still Justifies More Upside
Hecla Mining and Coeur Mining Spike 13% as Treasury Buyback Plan Ignites Precious Metals Rally
Which Silver Mining ETF Is the Better Buy: Global X's SIL or iShares' SLVP?
Surface Sampling Just Extended an Ontario Gold Trend to 560 Metres
Coeur Mining: A Guidance Cut Doesn't Change The Bigger Picture
Which Precious Metals ETF Is the Better Buy: Global X's Silver Miners SIL or iShares' Gold Trust IAU?
Assenagon Asset Management S.A. Sells 707,062 Shares of Coeur Mining, Inc. $CDE
Coeur Mining, Inc. $CDE Shares Sold by Cetera Investment Advisers
Coeur Mining Q2 Earnings Call Highlights
Is Coeur Mining Inc (CDE) Overvalued After 11.1% Rally? GF Value Says Overvalued
Gold's Winning Streak: Navigating Your ETF Options
Coeur Mining Q2 Earnings Call Flags Slower Canadian Ramp-Ups
Terrible Jobs Report Sparks Rally In AI and Tech: 10 Stocks Leading Friday's Surge
Coeur Mining, Inc. (CDE) Q2 2026 Earnings Call Transcript
Procore Introduces Asset Register Within Asset Management to Simplify Handover from Contractor to Owner
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Coeur Reports Second Quarter 2026 Results
Coeur Mining Set to Report Q2 Earnings: Here's What to Expect